Zomedica Quick Ratio (ZOMDF) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Zomedica Corp   (NONE: ZOMDF)

Zomedica 's Quick Ratio

ZOMDF's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.84 below Zomedica Corp average.

Within Major Pharmaceutical Preparations industry 367 other companies have achieved higher Quick Ratio than Zomedica in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1926, from total ranking in the first quarter 2026 at 2503.

Explain Quick Ratio?
How much Cash & cash equivalents ZOMDF´s has?
What are ZOMDF´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZOMDF Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 14.6 % 15.57 % 1.26 % 4.56 % 0.26 %
Y / Y Cash & cash equivalent Change -9.09 % 6.02 % 28.43 % -23.09 % 5.37 %
Quick Ratio MRQ 0.84 1.09 0.95 0.89 1.06
ZOMDF's Total Ranking # 1926 # 2503 # 2409 # 2293 # 2161
Seq. Current Liabilities Change 5.19 % -9.43 % 12.06 % 7.35 % 6.08 %
Seq. Cash & cash equivalent Change -18.83 % 3.9 % 20.29 % -10.39 % -5.34 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 368
Healthcare Sector # 662
Overall Market # 2128


Quick Ratio Statistics
High Average Low
140.95 15.1 0.24
(Mar 31 2021)   (Dec 31 2019)




Financial Statements
Zomedica 's Current Liabilities $ 9 Millions Visit ZOMDF's Balance sheet
Zomedica 's Cash & cash equivalent $ 8 Millions Visit ZOMDF's Balance sheet
Source of ZOMDF's Sales Visit ZOMDF's Sales by Geography


Cumulative Zomedica 's Quick Ratio

ZOMDF's Quick Ratio for the trailling 12 Months

ZOMDF Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 8.53 % 5.08 % -0.29 % 16.51 % 20.86 %
Y / Y Cash & cash equivalent TTM Growth -1.42 % 2.1 % -5.42 % -23.71 % -36.64 %
Quick Ratio TTM 0.94 1 1.02 0.96 1.04
Total Ranking TTM # 1300 # 1469 # 1156 # 1121 # 1124
Seq. Current Liabilities TTM Growth 3.34 % 3.48 % 0.36 % 1.13 % 0.06 %
Seq. Cash & cash equivalent TTM Growth -2.22 % 1.58 % 6.29 % -6.63 % 1.27 %

Quick ratio ranking by company, industry and sector >> Back to ZOMDF Financial Strength Comparisons >> Go to Compare ZOMDF Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2026 to $9.00 millions, cumulative Quick Ratio decreased to 0.94 below the Zomedica Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 435 other companies have achieved higher Quick Ratio than Zomedica . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 2900.

Explain Quick Ratio?
How much Cash & cash equivalents ZOMDF´s has?
What are ZOMDF´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 436
Healthcare Sector # 894
Within the Market # 1926


trailing twelve months Quick Ratio Statistics
High Average Low
72.28 15.77 0.69
(Sep 30 2021)   (Mar 31 2019)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Tao Synergies Inc   2.30 $ 2.368  Millions$ 1.032  Millions
Madrigal Pharmaceuticals Inc   2.24 $ 839.419  Millions$ 374.204  Millions
Rockwell Medical inc   2.23 $ 24.936  Millions$ 11.174  Millions
Ars Pharmaceuticals Inc   2.22 $ 143.845  Millions$ 64.728  Millions
Alnylam Pharmaceuticals Inc   2.19 $ 3,308.147  Millions$ 1,512.513  Millions
Xeris Biopharma Holdings Inc   2.16 $ 243.494  Millions$ 112.826  Millions
Ardelyx inc   2.13 $ 281.830  Millions$ 132.220  Millions
Oragenics Inc   2.12 $ 3.864  Millions$ 1.822  Millions
Pacira Biosciences inc   2.06 $ 251.031  Millions$ 122.011  Millions
Genelux Corporation  2.05 $ 29.870  Millions$ 14.590  Millions
Opko Health Inc   2.01 $ 300.761  Millions$ 149.367  Millions
Corcept Therapeutics Inc  2.00 $ 308.197  Millions$ 153.802  Millions
Clene Inc   2.00 $ 9.700  Millions$ 4.852  Millions
Blue Water Vaccines Inc  2.00 $ 5.942  Millions$ 2.974  Millions
Vertex Pharmaceuticals Inc  1.99 $ 7,852.400  Millions$ 3,937.900  Millions
Metavia Inc   1.99 $ 12.636  Millions$ 6.346  Millions
Connect Biopharma Holdings Limited  1.93 $ 31.500  Millions$ 16.301  Millions
Amarin Corp Plcuk  1.92 $ 314.850  Millions$ 164.195  Millions
Mustang Bio inc   1.91 $ 15.150  Millions$ 7.918  Millions
Therapeuticsmd Inc   1.84 $ 9.189  Millions$ 5.003  Millions
Fortress Biotech Inc   1.81 $ 196.576  Millions$ 108.829  Millions
Maravai Lifesciences Holdings Inc   1.77 $ 70.091  Millions$ 39.519  Millions
Decoy Therapeutics Inc   1.77 $ 8.289  Millions$ 4.680  Millions
Hyperion Defi inc   1.75 $ 9.637  Millions$ 5.509  Millions
Verastem Inc   1.75 $ 136.400  Millions$ 78.130  Millions
Urogen Pharma Ltd   1.74 $ 108.000  Millions$ 61.915  Millions
Pyxis Oncology Inc   1.72 $ 47.141  Millions$ 27.474  Millions
Ernexa Therapeutics Inc   1.71 $ 5.028  Millions$ 2.932  Millions
Lantern Pharma Inc   1.70 $ 7.361  Millions$ 4.323  Millions
Nuvectis Pharma inc   1.67 $ 22.160  Millions$ 13.294  Millions

Date modified: 2026-09-13T23:46:08+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.